471 results about "Diagnostic marker" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of secretory lactase-like protein (LCTL) as a diagnostic marker in preparation of a diagnostic kit for chronic kidney diseases. According to the present invention, the secretory form of the LCTL is found for the first time, the secretory LCTL content in the human serum is detected by using the existing commercial ELISA kit for the first time, and the further research finds that the secretory LCTL content in the serum of the chronic kidney disease patient is significantly reduced compared with the normal person; and the content of the LCTL in the serum is obviously related to the renal function impairment degree and proteinuria degree of the patient, so that the application of the secretory LCTL in preparing the biomarker for diagnosing the chronic kidney disease is provided for the first time. The invention provides a new method for chronic kidney disease diagnosis, and has important clinical significance and commercial value.

The invention discloses a novel tsRNA high-sensitivity detection kit based on CRISPR (clustered regularly interspaced short palindromic repeats) / Cas13a-Cas14a, and belongs to the field of tumor marker detection. The tsRNA (tRNA-derived small RNA) is a diagnostic marker which is found recently and has great potential. In order to realize the clinical transformation of tsRNA as soon as possible, the tsRNA detection kit is developed on the basis of nuclease P1 combined with CRISPR / Cas13a-Cas14a linkage dual systems, and comprehensive, ultra-sensitive, high-specificity, low-cost and rapid tsRNA detection is realized through multiple signal amplification. Compared with the traditional technology, the sensitivity of the method is improved by 105-107 times, 1% of tsRNA in the mixture can be detected, and the method has more advantages in clinical application. Therefore, a new scheme is provided for application of the tsRNA in clinical diagnosis of diseases, and meanwhile, a reliable technology is provided for mechanism research of the tsRNA in occurrence and development of the diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a macrophage Angulin-1 gene and / or an Angulin-1 protein in preparation of medicines and diagnostic products for preventing and / or treating atherosclerosis and related diseases. Research finds that plaque and necrotic core areas of an atherosclerosis animal model are remarkably increased due to macrophage Angulin-1 gene knockout, and disease development is promoted; and the recovery of the expression level of Angulin-1 significantly inhibits the development of lesion. Cell experiments show that Angulin-1 reduces intake of oxidized low-density lipoprotein by down-regulating expression of macrophage LOX-1, so that formation of foam cells is inhibited. Therefore, the macrophage Angulin-1 can be used as an atherosclerosis drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The invention provides a diagnostic marker for systemic lupus erythematosus and application of the diagnostic marker, and belongs to the technical field of biological medicine. The diagnostic marker is at least one protein of PDGFA (Platelet Derivative Growth Factor Amplification), APOD (Adenosine Polymerase Chain Reaction), CFHR5, AMDHD1 and SCGB3A1; the amino acid sequence of the PDGFA is as shown in SED ID NO. 1; the amino acid sequence of the APOD is as shown in SED ID NO. 2; the amino acid sequence of the CFHR5 is as shown in SED ID NO.3; the amino acid sequence of AMDHD1 is as shown in SED ID NO. 4; and the amino acid sequence of the SCGB3A1 is as shown in SED ID (Sequence of Identification) NO.5. According to the present invention, the five proteins are adopted as the SLE disease diagnosis biomarker independently or in the combination manner, such that advantages of high accuracy, high sensitivity and high specificity are provided, and the new target spot is provided for the diagnosis, the intervention improvement and the like of the SLE patient.

The invention belongs to the technical field of biomedicine, and particularly relates to application of GPR161 as an acute distress syndrome diagnostic marker and a therapeutic target. Experiments prove that the expression level of GPR161 in peripheral blood mononuclear cells of a patient with the acute respiratory distress syndrome is remarkably increased, and the expression quantity of the GPR161 is positively correlated with the severity of the disease, so that the GPR161 gene or GPR161 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the acute respiratory distress syndrome; a reagent for inhibiting GPR161 gene expression or protein activity can be used for preparing a medicine for treating the acute respiratory distress syndrome. The invention provides a new strategy for diagnosis, monitoring and targeted drug development of ARDS, and has important clinical application value.

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.

The invention provides an electroencephalogram data transmission method combining lossless and lossy compression, belongs to the field of electroencephalogram data transmission and compression processing, and is used for solving the problems of low transmission efficiency of pure lossless compression and easy loss of key diagnosis information of pure lossy compression in related technologies. According to the method, multi-dimensional features of electroencephalogram data are extracted, a key area and a non-key area are divided, lossless compression and lossy compression processing are adopted respectively, the area division proportion is dynamically adjusted in combination with transmission bandwidth, signal features and application scenes, and corresponding data are transmitted through dual protocols. The transmission efficiency can be improved while the clinical diagnosis marker and the core characteristics are reserved, and the scene adaptability and the transmission reliability are achieved at the same time.

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.

The invention relates to a novel method for identifying a diagnostic marker peak of protein citrullination by mass spectrometry. A gas phase fragmentation pathway of citrullinated peptide is explored, a characteristic neutral loss is found, namely, the neutral loss of 43.0058 Da is matched with release of an isocyanate group of citrullinated ureido, the two modifications can be distinguished when the corresponding neutral loss is detected, and citrullinated modification can be accurately and quickly confirmed. When secondary mass spectrum data are retrieved, an anti-library is additionally added to calculate the false positive rate caused by random matching, and a common pollution library is added into a database to eliminate the influence of pollution protein in an identification result; the mass error tolerance is set in a targeted manner, and the accuracy of mass spectrum data retrieval and the diagnosis accuracy of protein citrullination are improved. The process of converting arginine into citrulline can be diagnosed with high specificity, the technology is a key technology for realizing polypeptide sequencing and post-translational modification analysis, and the specific citrulline part in the protein can be determined.

The invention provides a multi-element machine learning model-based cross-species lung disease characteristic gene screening method and system, an electronic system and a storage device. The method comprises the following steps of: acquiring single cell / transcriptome data related to mouse lung diseases from a public database and preprocessing the single cell / transcriptome data; training the model by adopting six machine learning algorithms and outputting a gene importance score; calculating the weight according to the model performance and normalizing the score; and integrating the cross-species scores through a weighted fusion formula, and outputting a feature gene list and a visual report. The system comprises a data acquisition and preprocessing module, a multi-element machine learning model training module, a weight calculation and normalization module, a cross-species comprehensive scoring module and a result output module. The screening accuracy, stability and generalization ability are improved through multi-algorithm integration and cross-species fusion, and the method can be widely applied to the fields of mechanism research of lung diseases, diagnosis marker development and drug target verification.

The invention belongs to the technical field of biomedicine, and particularly relates to application of DHX58 as a diagnostic marker and a therapeutic target of rheumatoid arthritis. Experiments prove that the DXH58 level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably increased, DHX58 and rheumatoid arthritis are positively correlated, and the DHX58 gene or DHX58 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of rheumatoid arthritis. Experiments prove that the targeted DHX58 can be used as an effective way for treating rheumatoid arthritis. The application has important meanings for researching the effect of DHX58 in rheumatoid arthritis, understanding the mechanism of RA disease and developing a new treatment strategy.

The invention belongs to the technical field of biological medicine, and particularly relates to application of macrophage LSR gene and / or LSR protein in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Research finds that the LSR deletion of macrophages aggravates renal injury by promoting inflammatory response of diabetic nephropathy and increasing lipid renal toxicity; on the contrary, after the LSR expression of the macrophages is recovered, the inflammatory response and lipid droplet deposition of the kidney of the diabetic nephropathy mouse can be effectively reduced, and meanwhile, the kidney injury is improved. Cell experiments show that LSR deletion of macrophages can activate a YAP signal channel to increase secretion of inflammatory factors and reduce low-density lipoprotein uptake at the same time. Therefore, the macrophage LSR can be used as a diabetic nephropathy drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The present invention relates to: a biomarker composition comprising AMPD3 for predicting sensitivity to a therapeutic agent for neurofibromatosis (NF1); a pharmaceutical composition comprising an AMPD3 inhibitor for preventing or treating NF1; and use thereof. The composition according to one aspect is highly useful as a diagnostic marker for therapeutic agent sensitivity in patients with NF1, and can be used as a new therapeutic target for NF1.

The invention discloses application of a diagnostic marker in preparation of a rheumatoid arthritis diagnostic product and a diagnostic system, and relates to the technical field of rheumatoid arthritis diagnosis. And the diagnostic marker comprises KMT2B, KMT2C, IFITM3, ECHS1, LYMPH%, MONO%, PDW, Path.CAST, RDW and RDW%. The diagnosis marker provided by the invention has extremely high diagnosis efficiency and has a good application prospect in the field of diagnosis of rheumatoid arthritis.

The invention provides an application of human source circular RNA hsacirc0083796 in preparation of a diagnostic reagent or a medicine for diagnosing and / or treating aortic dissection. The invention also provides a kit for diagnosing the aortic dissection. The invention also provides a pharmaceutical composition for treating aortic dissection. According to the application of the human source circular RNA in preparation of heart disease related products, the related heart disease related circular RNA (circled-Frizzled class receptor 3, hsacirc0083796) is one of circular RNAs with the highest expression quantity in the blood of aortic dissection patients and has high conservative property, the function of the circular RNA is closely related to heart diseases, and the circular RNA has a good application prospect in preparation of heart disease related products. The method has great significance in diagnosis and treatment of heart diseases. Meanwhile, due to the stable and specific properties of the circular RNA, compared with other types of markers, the circular RNA has larger abundance in body fluid of a patient and more obvious change, so that the circular RNA has the potential of becoming a novel diagnostic marker.

A method of automatically diagnosing pneumonia in a patient includes obtaining values of two or more diagnostic parameters of the patient from a caregiver of the patient using an input / output interface device. The method includes applying, using a processor connected to an input / output interface, two or more diagnostic parameters to an electronic memory storing a plurality of pre-compiled pneumonia diagnostic models to identify an optimal diagnostic model for performing the diagnosis. The values of the two or more diagnostic markers are applied to the identified optimal diagnostic model to generate a diagnostic output. An input / output interface device is operated according to the diagnostic output to indicate to the caregiver the presence or absence of pneumonia in the patient. The caregiver may use the diagnostics to provide appropriate care for the patient. A pneumonia diagnostic model is from investigations of pneumonia-positive and non-pneumonia population of subjects.

The invention discloses a progressive multiple sclerosis differential diagnosis marker based on immunophenomics and application of the progressive multiple sclerosis differential diagnosis marker. The invention specifically provides an immune biomarker set for identifying progressive or recurrent remission type multiple sclerosis and a corresponding reagent and kit thereof. The immune biological marker provided by the invention comprises one or more of the following groups: a) activating a T cell subset; b) a CD28 < + > and CD28-T cell subset; c) forming a subgroup by the CD8 + T cells; and d) a MAIT cell subset category. The immune biomarker disclosed by the invention can also be applied in a multi-index combination manner, and can be applied to a) multiple sclerosis patients which are not subjected to disease modification treatment; b) a patient with multiple sclerosis treated by disease modification; and c) a very good effect of distinguishing clinical subtypes of the multiple sclerosis can be achieved in the three types of people of the multiple sclerosis patients who do not distinguish whether the multiple sclerosis patients are subjected to the disease modification treatment or not.

Disclosed are a composition and method for the diagnosis of diseases accompanied by impaired glucose tolerance, comprising a material for ITIH1 detection. The composition and method according to the present application enable a relatively sensitive response even to small changes in blood sugar according to various stimulants in a hyperglycemic situation as compared to glycated hemoglobin (HbA1c) which is an existing diagnostic marker widely used for patients with diabetes, which is a typical disease accompanied by impaired glucose tolerance, and thus can more precisely detect blood sugar changes under various stress situations.

The invention relates to the field of biomarkers, and particularly provides a polycystic ovarian syndrome pregnancy outcome diagnosis marker and application thereof. According to the present invention, the endometrial targeting metabonomics research is adopted to screen the disease-related potential metabolic markers such as N-Acetylaspartic acid, Suberic acid and isoallolithocholic acid, and the three metabolites are subjected to quantitative detection so as to accurately predict the pregnancy outcome of the polycystic ovarian syndrome patient, such that the pregnancy outcome of the polycystic ovarian syndrome patient can be accurately predicted, and the prediction of the pregnancy outcome of the polycystic ovarian syndrome patient can be easily achieved, such that the disease-related potential metabolic markers such as N-Acetylaspartic acid, suberic acid and isoallolithocholic acid can be provided. A new path is provided for early intervention of the disease state to improve the pregnancy outcome, and a new drug target is provided for evaluation of the endometrial function of the polycystic ovarian syndrome.

The present invention discloses an application of a long non-coding RNA in serum exosomes as a diagnostic marker for non-small cell lung cancer, characterized in that the long non-coding RNA is the AL139294.1 gene, and its nucleotide sequence is shown in SEQ ID NO.1; the application of the non-small cell lung cancer diagnostic marker in the preparation of a molecular targeted drug for non-small cell lung cancer or a non-small cell lung cancer diagnostic kit, wherein the diagnostic kit comprises a pair of specific amplification primers for detecting the expression amount of the lncRNA AL139294.1 gene in serum exosomes, and the specific nucleotide sequences are as follows: upstream amplification primer: 5'-TGTCACAGCAGATGCCACA T-3'; downstream amplification primer: 5'-CCCACTCGCTGCCTATAACA-3'; the advantages are high sensitivity and specificity and positive correlation with the prevalence of non-small cell lung cancer.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The present invention relates to a method, in particular an in vitro method, for identifying an improved anti-senescence compound based on detecting the binding of said compound in the presence of at least one phosphory lated amino acid in the transcription activation domain (TAD) domain of mammalian protein p53. The present invention further relates to a method, in particular an in vitro method, for monitoring an anti-senescence treatment or prophylaxis in a mammalian subject in need thereof, based on detecting the amount of phosphorylation of amino acids in the TAD and / or C-terminal region of the mammalian p53 protein in a biological sample obtained from said subject and / or detecting the amount and / or co-localization with phosphorylated p53 of the promyelocytic leukemia protein (PML) bodies in a biological sample obtained from said subject. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof. Finally, improved anti-senescence compounds or pharmaceutical compositions are provided.

The present application relates to the technical field of diagnostic markers, in particular to a marker combination and its application in diagnosing active tuberculosis and distinguishing between latent tuberculosis infection and active tuberculosis. The lectin combination provided by the present application can be used as a marker for ATB diagnosis and distinguishing between LTBI and ATB, and has high specificity and sensitivity. The lectin combination provided by the present application in combination with detection of specific antibodies of mycobacterium tuberculosis antigens can further improve the diagnostic effect. The marker and its detection products provided by the present application have good application potential in ATB diagnosis and distinguishing between LTBI and ATB, and are expected to overcome the limitations of existing diagnostic techniques, improve the diagnostic accuracy and sensitivity of tuberculosis, and provide new ideas and technical means for early detection, precise treatment and effective prevention and control of tuberculosis.

The invention discloses a colorectal cancer diagnostic marker group based on expiration volatile organic compounds and application of the colorectal cancer diagnostic marker group. The colorectal cancer diagnostic marker group consists of six expiration volatile organic compounds, namely furfural, 2-methyl butane, valeric acid, methyl allyl sulfide, hexane and octanal. According to the method, expiration samples of 182 subjects are analyzed through TD-GC-MS / MS, machine learning is combined, the six expiration volatile organic compounds are screened out, the diagnosis AUC of the combination in a verification queue reaches 0.907, the accuracy rate is 0.806, and the combination is superior to a serum marker combination (AUC = 0.861). The invention further provides the BRS and a colorectal cancer noninvasive diagnosis and risk stratification system, and the BRS and the colorectal cancer noninvasive diagnosis and risk stratification system are used for achieving efficient prediction and risk stratification of the colorectal cancer. Compared with a traditional risk scoring model depending on clinical variables such as age, family history and lifestyle, the BRS provides unique metabonomics information, and the prediction accuracy is remarkably improved.

The present invention discloses a set of diagnostic markers for aortic dissection and their applications. The markers include the genes MMP8, ALOX15, HP, FXYD2, SIGLEC8, and CCL2. The genes MMP8, ALOX15, HP, FXYD2, SIGLEC8, and CCL2 protected by the present invention can be used as biomarkers for AD and as indicators for assessing disease severity in AD patients, enabling efficient diagnosis of patients with aortic dissection.

The application belongs to the technical field of biotechnology, and particularly relates to a colorectal cancer high liver metastasis cell line and a preparation method and application thereof. The cell line was preserved in the China Center for Type Culture Collection on January 14, 2026, and the preservation number is CCTCC NO: C202618. The cell line is derived from a mouse colorectal cancer cell line MC38, and is constructed by lentivirus transfection to express luciferase stably, and is obtained by continuously performing at least five rounds of liver metastasis tumor orthotopic iteration screening in C57BL / 6 mice through rectal submucosal injection. The MC38-P06 cell line provided by the application has a significantly enhanced liver metastasis ability, a shorter MC38-P01 model time, a higher liver tumor load, and a shorter mouse survival period, and can be used for screening and evaluating anti-liver metastasis drugs, researching liver microenvironment regulation mechanisms, and identifying liver metastasis related diagnostic markers.

The present invention relates to a T cell activation inhibiting factor (VISTA) protein or mRNA containing a V-type immunoglobulin domain, as a diagnostic marker selected for treatment of a patient with an autoimmune disorder, and as a means for monitoring the success of treatment of an autoimmune disorder. The present invention relates to methods for patient selection and treatment monitoring, to combined diagnostic and therapeutic applications for determining VISTA protein and / or mRNA in a patient sample, and to diagnostic kits suitable for use in the methods of the invention.

The invention belongs to the technical field of biomedicine, and particularly relates to a diagnostic marker for lung transplantation rejection and application of the diagnostic marker. The invention discloses one or more of OIT3, CAMP, USP4, IPO9 and PON1 as markers for diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection for the first time, and diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection can be realized by detecting the content, expression quantity and / or activity of the markers. The invention discloses that the OIT3 can be used as a diagnosis and treatment target of the lung transplantation rejection for the first time, and diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection can be realized by detecting the content, expression quantity and / or activity of the OIT3; the lung transplantation rejection reaction can be prevented and / or treated through the OIT inhibitor.

To provide a diagnosis marker for a non-alcoholic fat liver disease.SOLUTION: The present invention relates to a composition and a kit for accurately diagnosing hepatitis (Non-alcoholic steatohepatitis;NASH) by including a formulation for measuring the level of ApoA-1 (Exosomal ApoA-1) protein derived from exosome, and relates to a composition and a kit for accurately predicting the prognosis after a medicine for treating non-alcoholic fat hepatitis is provided.SELECTED DRAWING: Figure 10

The invention discloses a gene marker for diagnosing latent tuberculosis infection and application of the gene marker, and belongs to the technical field of biological medicine. According to the present invention, the latent tuberculosis infection early diagnosis marker is screened based on the peripheral blood whole genome DNA methylation map, the new target is provided for the diagnosis of latent tuberculosis infection, the diagnosis efficiency of the marker is evaluated through pyrosequencing, the corresponding detection kit and the use method are developed, and the rapid and accurate diagnosis of latent tuberculosis infection is achieved.